Fujifilm signs manufacturing contract with U.S. firm VLP for COVID-19 vaccine By Reuters


© Reuters. FILE PHOTO: Fujifilm’s company logo is seen at its exhibition hall nearby the headquarters of Fujifilm Holdings Corp in Tokyo

TOKYO (Reuters) – Fujifilm Holdings Corp (T:) said on Thursday that it had signed a manufacturing contract agreement with U.S.-based firm VLP Therapeutics for a COVID-19 vaccine formulation.

Japan’s Fujifilm will use its manufacturing facilities and infrastructure to handle development of the vaccine for clinical trials, the two companies said in a statement.

VLP’s RNA-based vaccine candidate was selected for funding by the Japan Agency for Medical Research and Development.

The biotech firm has a Japanese subsidiary which is involved in drug research with government bodies and universities.

Fujifilm has been increasingly shifting into healthcare over the past decade from its traditional photography and office solutions businesses.

Last month, it concluded a successful Phase-3 clinical trial of its Avigan drug for use in COVID-19 patients.

A Fujifilm unit is also involved in making ingredients for Novavax Inc’s (O:) coronavirus vaccine candidate.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*